

## Supplementary Figures

### **Integrative Multi-Omics Flux Analysis Reveals Metabolic Mechanisms of Isoniazid-Induced Liver Toxicity**

Zita Soons<sup>1\*</sup>, A. Zeynep Sayin<sup>1</sup>, Lars M. Blank<sup>2</sup>, Adrian Roth<sup>3</sup>, Marco Oldiges<sup>4</sup>, Henrik Cordes<sup>1§</sup>, Lars Kuepfer<sup>1§</sup>

<sup>1</sup>University Hospital RWTH Aachen, Institute for Systems medicine with Focus on Organ Interaction, Pauwelsstraße 19, 52074 Aachen, Germany

<sup>2</sup>RWTH Aachen, Institute of Applied Microbiology, Worringerweg 1, 52074 Aachen, Germany


<sup>3</sup>F. Hoffmann-La Roche Ltd, Precision Safety, Product Development Safety, Grenzacherstrasse 124, CH-4070 Basel, Switzerland

<sup>4</sup>Forschungszentrum Jülich GmbH, Institute of Bio- and Geosciences (IBG-1: Biotechnology), Wilhelm-Johnen-Straße.52428 Jülich, Germany

\*Corresponding author


§Shared last authors

Email: [zsoons@ukaachen.de](mailto:zsoons@ukaachen.de)




**Supplementary Figure 1. BPK-based assay setup and reverse dosimetry**

In vitro assay design to mimic organ-specific in vivo drug exposure. **A.** Dose-response experiments in human liver microtissues to identify a toxic exposure causing 20% reduction in cell viability. **B.** PBPK-based reverse dosimetry to estimate the in vivo daily dose producing equivalent hepatic exposure. **C.** Translation of continuous PBPK exposure profiles into an experimental dosing regimen with three daily media changes.




**Supplementary figure 2. Scatterplot of log<sub>2</sub>-transformed protein vs. gene expression across all samples.** Pearson correlation coefficient  $r = 0.32$ .




**Supplementary Figure 3. Metascape enrichment analysis**

Top 20 enriched terms identified by Metascape. **A.** Differentially expressed proteins (DEPs) under therapeutic exposure. **B.** DEPs under toxic exposure. **C.** Differentially expressed genes (DEGs) under therapeutic exposure. **D.** DEGs under toxic exposure.




**Supplementary Fig. 4. Context- specific models inferred from transcriptomics.**

Context-specific models inferred from transcriptomics and metabolic constraints for therapeutic, toxic, and DMSO control conditions. Each dot represents one of 100 alternative optimal model reconstructions. **A.** Model size (number of active reactions). **B.** Pairwise Jaccard index relative to T0 **C.** Pairwise Pearson correlation coefficients of flux capacities relative to T0.




### Supplementary Figure 5. Context- specific models inferred from proteomics.

Pairwise Jaccard index relative to T0 for context-specific models inferred from proteomics and metabolic constraints for therapeutic, toxic, and DMSO control conditions. Each dot represents one of 100 alternative optimal model reconstructions.



### Supplementary figure 6. Integrated PCA analysis.

Pathway-level contributions to PC1 and PC2 per data layer (transcriptomics Tx, proteomics Px, fluxomics Fx), as well as their summed contribution. Pathway contributions are normalized by layer contribution; color scaling is relative to the mean contribution of each pathway.



**Supplementary Fig. 7. Cut-off selection for context-specific models.**

Reactions associated with expression above the mean plus one standard deviation were considered active, whereas reactions below the mean minus two standard deviations were considered inactive.